Vikesaa J, Hansen TV, Jonson L, Borup R, Wewer UM, Christiansen J, Nielsen FC: RNA-binding IMPs promote cell adhesion and invadopodia formation. Embo J. 2006, 25 (7): 1456-1468. 10.1038/sj.emboj.7601039.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen FC: A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol. 1999, 19 (2): 1262-1270.
Article
CAS
PubMed
PubMed Central
Google Scholar
Liao B, Hu Y, Herrick DJ, Brewer G: The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem. 2005, 280 (18): 18517-18524. 10.1074/jbc.M500270200.
Article
CAS
PubMed
Google Scholar
Monk D, Bentley L, Beechey C, Hitchins M, Peters J, Preece MA, Stanier P, Moore GE: Characterisation of the growth regulating gene IMP3, a candidate for Silver-Russell syndrome. J Med Genet. 2002, 39 (8): 575-581. 10.1136/jmg.39.8.575.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mueller-Pillasch F, Pohl B, Wilda M, Lacher U, Beil M, Wallrapp C, Hameister H, Knochel W, Adler G, Gress TM: Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev. 1999, 88 (1): 95-99. 10.1016/S0925-4773(99)00160-4.
Article
CAS
PubMed
Google Scholar
Noske A, Faggad A, Wirtz R, Darb-Esfahani S, Sehouli J, Sinn B, Nielsen FC, Weichert W, Buckendahl AC, Roske A, et al: IMP3 expression in human ovarian cancer is associated with improved survival. Int J Gynecol Pathol. 2009, 28 (3): 203-210. 10.1097/PGP.0b013e318189a724.
Article
PubMed
Google Scholar
Bellezza G, Cavaliere A, Sidoni A: IMP3 expression in non-small cell lung cancer. Hum Pathol. 2009, 40 (8): 1205-1206. 10.1016/j.humpath.2009.03.019.
Article
PubMed
Google Scholar
Xu H: IMP3: a diagnostic and prognostic biomarker in malignant melanoma. Expert Rev Mol Diagn. 2008, 8 (5): 557-558. 10.1586/14737159.8.5.557.
Article
CAS
PubMed
Google Scholar
Do SI, Kim YW, Park HR, Park YK: Expression of insulin-like growth factor-II mRNA binding protein 3 (IMP3) in osteosarcoma. Oncol Res. 2008, 17 (6): 269-272. 10.3727/096504008786991639.
Article
PubMed
Google Scholar
Schaeffer DF, Owen DR, Lim HJ, Buczkowski AK, Chung SW, Scudamore CH, Huntsman DG, Ng SS, Owen DA: Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival. BMC Cancer. 2010, 10: 59-10.1186/1471-2407-10-59.
Article
PubMed
PubMed Central
Google Scholar
Levy M, Lin F, Xu H, Dhall D, Spaulding BO, Wang HL: S100P, von Hippel-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy. Hum Pathol. 2010,
Google Scholar
Findeis-Hosey JJ, Yang Q, Spaulding BO, Wang HL, Xu H: IMP3 expression is correlated with histologic grade of lung adenocarcinoma. Hum Pathol. 2010, 41 (4): 477-484. 10.1016/j.humpath.2009.10.004.
Article
CAS
PubMed
Google Scholar
Mentrikoski MJ, Ma L, Pryor JG, McMahon LA, Yang Q, Spaulding BO, Scott GA, Wang HL, Xu H: Diagnostic utility of IMP3 in segregating metastatic melanoma from benign nevi in lymph nodes. Mod Pathol. 2009, 22 (12): 1582-1587. 10.1038/modpathol.2009.128.
Article
CAS
PubMed
Google Scholar
Yuan RH, Wang CC, Chou CC, Chang KJ, Lee PH, Jeng YM: Diffuse expression of RNA-binding protein IMP3 predicts high-stage lymph node metastasis and poor prognosis in colorectal adenocarcinoma. Ann Surg Oncol. 2009, 16 (6): 1711-1719. 10.1245/s10434-009-0446-0.
Article
PubMed
Google Scholar
Li L, Xu H, Spaulding BO, Cheng L, Simon R, Yao JL, di Sant'Agnese PA, Bourne PA, Huang J: Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and urothelial tumors. Hum Pathol. 2008, 39 (8): 1205-1211. 10.1016/j.humpath.2007.12.012.
Article
CAS
PubMed
Google Scholar
Li C, Zota V, Woda BA, Rock KL, Fraire AE, Jiang Z, Lu D, Xu B, Dresser K, Lutman CV, et al: Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations. Mod Pathol. 2007, 20 (12): 1263-1268. 10.1038/modpathol.3800960.
Article
CAS
PubMed
Google Scholar
Simon R, Bourne PA, Yang Q, Spaulding BO, di Sant'Agnese PA, Wang HL, Xu H: Extrapulmonary small cell carcinomas express K homology domain containing protein overexpressed in cancer, but carcinoid tumors do not. Hum Pathol. 2007, 38 (8): 1178-1183. 10.1016/j.humpath.2007.02.001.
Article
CAS
PubMed
Google Scholar
Slosar M, Vohra P, Prasad M, Fischer A, Quinlan R, Khan A: Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors. Endocr Pathol. 2009, 20 (3): 149-157. 10.1007/s12022-009-9079-x.
Article
CAS
PubMed
Google Scholar
Walter O, Prasad M, Lu S, Quinlan RM, Edmiston KL, Khan A: IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype. Hum Pathol. 2009, 40 (11): 1528-1533. 10.1016/j.humpath.2009.05.005.
Article
CAS
PubMed
Google Scholar
Li D, Yan D, Tang H, Zhou C, Fan J, Li S, Wang X, Xia J, Huang F, Qiu G, et al: IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Ann Surg Oncol. 2009, 16 (12): 3499-3506. 10.1245/s10434-009-0648-5.
Article
PubMed
Google Scholar
Kobel M, Xu H, Bourne PA, Spaulding BO, Shih Ie M, Mao TL, Soslow RA, Ewanowich CA, Kalloger SE, Mehl E, et al: IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Mod Pathol. 2009, 22 (3): 469-475. 10.1038/modpathol.2008.206.
Article
PubMed
Google Scholar
Lu D, Vohra P, Chu PG, Woda B, Rock KL, Jiang Z: An oncofetal protein IMP3: a new molecular marker for the detection of esophageal adenocarcinoma and high-grade dysplasia. Am J Surg Pathol. 2009, 33 (4): 521-525. 10.1097/PAS.0b013e31818aada9.
Article
PubMed
Google Scholar
Riener MO, Fritzsche FR, Clavien PA, Pestalozzi BC, Probst-Hensch N, Jochum W, Kristiansen G: IMP3 expression in lesions of the biliary tract: a marker for high-grade dysplasia and an independent prognostic factor in bile duct carcinomas. Hum Pathol. 2009, 40 (10): 1377-1383. 10.1016/j.humpath.2009.01.024.
Article
CAS
PubMed
Google Scholar
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 2007, 57 (1): 43-66. 10.3322/canjclin.57.1.43.
Article
PubMed
Google Scholar
Carroll PR: Early stage prostate cancer--do we have a problem with over-detection, overtreatment or both?. J Urol. 2005, 173 (4): 1061-1062. 10.1097/01.ju.0000156838.67623.10.
Article
PubMed
Google Scholar
Andren O, Fall K, Franzen L, Andersson SO, Johansson JE, Rubin MA: How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol. 2006, 175 (4): 1337-1340. 10.1016/S0022-5347(05)00734-2.
Article
PubMed
Google Scholar
Nilsson KP, Ikenberg K, Aslund A, Fransson S, Konradsson P, Rocken C, Moch H, Aguzzi A: Structural typing of systemic amyloidoses by luminescent-conjugated polymer spectroscopy. Am J Pathol. 176 (2): 563-574. 10.2353/ajpath.2010.080797.
Nielsen FC, Nielsen J, Christiansen J: A family of IGF-II mRNA binding proteins (IMP) involved in RNA trafficking. Scand J Clin Lab Invest Suppl. 2001, 234: 93-99.
Article
CAS
PubMed
Google Scholar
Kristiansen G, Pilarsky C, Pervan J, Sturzebecher B, Stephan C, Jung K, Loening S, Rosenthal A, Dietel M: CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate. 2004, 58 (2): 183-192. 10.1002/pros.10324.
Article
PubMed
Google Scholar
Nemunaitis J, Meyers T, Senzer N, Cunningham C, West H, Vallieres E, Anthony S, Vukelja S, Berman B, Tully H, et al: Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. Mol Ther. 2006, 13 (6): 1185-1191. 10.1016/j.ymthe.2006.01.013.
Article
CAS
PubMed
Google Scholar